share_log

Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12

Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12

富国银行将C4 Therapeutics的评级上调至增持,并将价格目标提高至12美元。
Benzinga ·  12/19 20:43  · 评级/大行评级

Wells Fargo analyst Derek Archila upgrades C4 Therapeutics (NASDAQ:CCCC) from Equal-Weight to Overweight and raises the price target from $8 to $12.

富国银行分析师德里克·阿基拉将C4 Therapeutics(纳斯达克:CCCC)的评级从同等权重上调至增持,并将目标价格从8美元提升至12美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发